$XBI $126.17 +3.5%
Pipeline Updates
$GILD Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer. source
$RETA Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome. source
$PSTV PLUS THERAPEUTICS, Inc. - The American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting: Image-Guided Rhenium-186 NanoLiposome (186RNL) Brachytherapy In The Treatment Of Recurrent Glioblastoma: Technique, Image Analysis, Dosimetry, And Monitoring. source
$TFFP TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19. source
$SPRO Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis. source
$CADL Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer. source
$INCY Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo. source
$ETON Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid. source
$XENT First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe. source
$RFL Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia. source
$LABP LANDOS BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN A PHASE 1 STUDY OF LABP-104 FOR SYSTEMIC LUPUS ERYTHEMATOSUS. source
$PFE & BNTX Pfizer And BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs. source
$IMUX Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis. source
$EWTX Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients. source
$CYDY CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA. source
$PHAT Phathom Pharmaceuticals Withdraws Public Offering. source
$HCM HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China. source
Posted by DV
Коментарі